Mersana Therapeutics, Inc.

DB:0M4 Stock Report

Market Cap: €156.8m

Mersana Therapeutics Management

Management criteria checks 2/4

Mersana Therapeutics' CEO is Marty Huber, appointed in Sep 2023, has a tenure of 1.33 years. total yearly compensation is $3.04M, comprised of 6.4% salary and 93.6% bonuses, including company stock and options. directly owns 0.094% of the company’s shares, worth €147.62K. The average tenure of the management team and the board of directors is 4.4 years and 7.7 years respectively.

Key information

Marty Huber

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage6.4%
CEO tenure1.3yrs
CEO ownership0.09%
Management average tenure4.4yrs
Board average tenure7.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Marty Huber's remuneration changed compared to Mersana Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$75m

Jun 30 2024n/an/a

-US$105m

Mar 31 2024n/an/a

-US$135m

Dec 31 2023US$3mUS$194k

-US$172m

Sep 30 2023n/an/a

-US$197m

Jun 30 2023n/an/a

-US$215m

Mar 31 2023n/an/a

-US$213m

Dec 31 2022US$163kn/a

-US$204m

Sep 30 2022n/an/a

-US$208m

Jun 30 2022n/an/a

-US$194m

Mar 31 2022n/an/a

-US$183m

Dec 31 2021US$290kn/a

-US$170m

Sep 30 2021n/an/a

-US$150m

Jun 30 2021n/an/a

-US$127m

Mar 31 2021n/an/a

-US$106m

Dec 31 2020US$303kn/a

-US$88m

Compensation vs Market: Marty's total compensation ($USD3.04M) is above average for companies of similar size in the German market ($USD890.74K).

Compensation vs Earnings: Marty's compensation has increased whilst the company is unprofitable.

CEO

Marty Huber (63 yo)

1.3yrs

Tenure

US$3,044,085

Compensation

Dr. Martin H. Huber, also known as Marty, M.D., is President and Chief Executive Officer at Mersana Therapeutics, Inc. since September 2023. He served as President and Head of R&D at Xilio Therapeutics, In...

Leadership Team

NamePositionTenureCompensationOwnership
Martin Huber
President1.3yrsUS$3.04m0.094%
€ 147.6k
Brian DeSchuytner
Senior VP5.5yrsUS$1.74m0.077%
€ 120.3k
Timothy Lowinger
Senior VP and Chief Science & Technology Officer16.9yrsUS$1.69m0.19%
€ 299.0k
Alejandra Carvajal
Senior VP3.8yrsUS$1.61m0.052%
€ 80.9k
Mohan Bala
Senior VP & Chief Development Officer3.3yrsUS$1.58m0.044%
€ 69.4k
Mikhail Papisov
Co-Founderno datano datano data
Ashish Mandelia
Chief Accounting Officer5.3yrsno data0.039%
€ 60.6k
Jason Fredette
Senior Vice President of Investor Relations & Corporate Communicationsno datano datano data
Chuck Miller
Senior Vice President of Regulatory Affairs4.4yrsno datano data
Marc Damelin
Exe. Director and Head of Biologyno datano datano data

4.4yrs

Average Tenure

54.5yo

Average Age

Experienced Management: 0M4's management team is considered experienced (4.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Martin Huber
President4.8yrsUS$3.04m0.094%
€ 147.6k
David Mott
Independent Chairman12.5yrsUS$329.93k0.47%
€ 740.8k
Peter Kiener
Member of the Scientific Advisory Boardno datano datano data
Lawrence Alleva
Independent Director7.3yrsUS$308.93k0.0017%
€ 2.7k
Willard Dere
Independent Director6.8yrsUS$305.43k0.020%
€ 31.4k
Kristen Hege
Independent Director8.4yrsUS$293.43k0%
€ 0
Anna Protopapas
Director9.8yrsUS$4.65m0.34%
€ 534.2k
Andrew A. Hack
Independent Director8yrsUS$297.43k0%
€ 0
Misti Ushio
Board Observerno datano datano data
Howard Burris
Member of the Scientific Advisory Boardno datano datano data
Allene Diaz
Independent Director3.8yrsUS$294.93k0%
€ 0
K. Wittrup
Member of Scientific Advisory Boardno datano datano data

7.7yrs

Average Tenure

60.5yo

Average Age

Experienced Board: 0M4's board of directors are considered experienced (7.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 06:08
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mersana Therapeutics, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Thomas ShraderBTIG
Justin ZelinBTIG